Page last updated: 2024-08-24

oseltamivir and Auricular Fibrillation

oseltamivir has been researched along with Auricular Fibrillation in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Fukushima, T; Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Kawai, S; Matsumoto, A; Onozato, M; Sugiyama, A; Takei, Y1
Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Leitz, P; Mittelstedt, A; Wolfes, J1
Hagiwara, M; Nozaki, S; Sugiyama, A; Suzuki, S; Takahara, A1

Other Studies

3 other study(ies) available for oseltamivir and Auricular Fibrillation

ArticleYear
Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model.
    Journal of pharmacological sciences, 2022, Volume: 148, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Repositioning; Electrophysiological Phenomena; Female; Hemodynamics; Infusions, Intravenous; Oseltamivir

2022
The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.
    Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:11

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Heart; Humans; In Vitro Techniques; Influenza, Human; Oseltamivir; Rabbits

2017
Electrophysiological effects of an anti-influenza drug oseltamivir on the guinea-pig atrium: comparison with those of pilsicainide.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:10

    Topics: Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Atrial Function; Atrial Function, Left; Atrial Function, Right; Electrophysiological Phenomena; Guinea Pigs; Heart Atria; Humans; Influenza, Human; Lidocaine; Oseltamivir; Potassium Channel Blockers; Refractory Period, Electrophysiological; Sodium Channel Blockers

2013